EMERYVILLE, Calif., Oct. 11, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has appointed Gail Maderis to its Board of Directors. Ms. Maderis will replace Harry F. Hixson, Jr., Ph.D.
